View Post

Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Alice Melão From: breastcancer-news.com The investigator-sponsored trial studying a combination of NeuVax (nelipepimut-S, NPS) and Herceptin (trastuzumab) as a maintenance treatment for HER2-positive breast cancer at high risk of recurrence has completed patient enrollment, Sellas Life Sciences, NeuVax’s developer, has announced. Top-line data from the trial is expected by the end of 2019. “The completion of enrollment of this Phase 2 clinical …

View Post

Mayo Clinic sees 80% increase in breast cancer clinical trial enrollment with IBM Watson’s clinical trial matching system

In Clinical Trials by Barbara Jacoby

By: Julie Spitzer  From: beckershospitalreview.com Rochester, Minn-based Mayo Clinic enrolled more patients in its breast cancer clinical trials after implementing IBM Watson Health’s Watson for Clinical Trials Matching, a cognitive computing system, according to early results of use in Mayo’s oncology practice. Although clinical trials increase patients’ access to new, promising or emerging treatments, matching and enrolling them in trials …